10-Q: STERIS Q1 FY26 Earnings Soar on Strong Revenue Growth, Debt Reduction

STERIS plc reported robust first-quarter fiscal 2026 results with significant revenue growth, improved profitability, and strong cash flow, driven by all three segments and reduced debt.

Summary

• Total revenues increased by 8.7% to $1,391.1 million for the three months ended June 30, 2025, compared to $1,279.5 million in the prior year.
• Gross profit rose 9.7% to $628.0 million, with the gross profit percentage improving to 45.1% from 44.7% in the prior year.
• Income from operations surged 32.6% to $246.0 million, up from $185.5 million in the same period last year, primarily due to increased volume, pricing, and lower restructuring expenses.
• Diluted net income per share from continuing operations increased by 26.9% to $1.79, compared to $1.41 in the prior year.
• Net cash provided by operating activities was $420.0 million, a 38.3% increase from $303.7 million in the prior year.
• Free cash flow significantly increased by 66.8% to $326.5 million, up from $195.7 million in the prior year.
• The debt-to-total capital ratio improved to 21.5% at June 30, 2025, from 23.6% at March 31, 2025, and 26.7% at June 30, 2024.
• Cash dividends declared per ordinary share increased to $0.57 from $0.52 in the prior year.
• The company completed a tuck-in acquisition in the Healthcare segment for approximately $15.0 million during the quarter.
• Restructuring expenses decreased substantially to $1.8 million from $25.7 million in the prior year, reflecting the near completion of the Fiscal 2024-2025 Restructuring Plan.

Sentiment

Score: 8

Explanation: The company reported strong financial performance across key metrics, including significant revenue growth, improved profitability, and robust cash flow. The reduction in debt and the positive impact of restructuring efforts contribute to a very positive outlook, despite some increases in SG&A and tax rate.

Positives

• Strong revenue growth of 8.7% across all three segments (Healthcare, AST, Life Sciences), indicating broad-based market demand and effective pricing strategies.
• Improved gross profit margin (45.1% vs. 44.7%) driven by favorable pricing, productivity, and other cost reductions.
• Significant increase in income from operations (+32.6%) and diluted EPS from continuing operations (+26.9%), demonstrating enhanced operational efficiency and profitability.
• Substantial growth in cash flow from operations (+38.3%) and free cash flow (+66.8%), providing strong liquidity and financial flexibility.
• Reduced interest expense by $14.5 million due to a lower principal amount of debt outstanding, reflecting effective debt management following the Dental segment divestiture.
• Improved debt-to-total capital ratio to 21.5%, indicating a stronger balance sheet and reduced financial leverage.
• Healthcare segment backlog increased to $403.5 million from $362.0 million, suggesting strong future demand.
• Life Sciences segment backlog increased to $111.0 million from $72.2 million, also indicating robust future orders.
• Restructuring expenses were significantly lower ($1.8 million vs. $25.7 million), indicating the company is moving past the major costs of its efficiency initiatives.

Negatives

• The effective income tax rate increased to 23.3% from 20.1%, primarily due to changes in the geographic mix of projected profits and unfavorable changes in discrete items.
• Selling, general, and administrative expenses increased by 5.4%, primarily due to higher compensation and benefit costs, unfavorable foreign currency movements, and increased bad debt expense.
• The prior year period included a $18.8 million pre-tax gain on the sale of the Controlled Environment Certification Services (CECS) business, which did not recur in the current quarter.

Risks

• Operating costs, pressure on pricing (including from inflation), customer loss, and business disruption could be greater than expected, leading to erosion of profit margins.
• Difficulties in successfully integrating acquired businesses, including unknown liabilities or higher-than-expected integration costs.
• Changes in tax laws or interpretations, such as those associated with the One Big Beautiful Bill Act (OBBBA), or new income tax treaties, could increase consolidated tax liabilities.
• Compliance with laws, court rulings, regulations, or the outcome of pending or threatened litigation (e.g., ethylene oxide litigation) may delay new product introductions, impact production, or result in uncovered costs.
• Potential for international unrest, military conflicts, economic downturns, and currency fluctuations to adversely affect performance.
• Delays in receipt of orders, order cancellations, or issues in the manufacture or shipment of ordered products.
• Failure to realize anticipated growth, performance, productivity improvements, cost savings, or synergies from acquisitions, restructuring efforts, and divestitures.
• The level of indebtedness could limit financial flexibility or increase future borrowing costs.
• Effects of changes in credit availability and pricing, impacting the company's and its customers'/suppliers' ability to access credit.
• Increasing competition within the industry may exert pressure on pricing or decrease demand for products and services.
• Labor-related issues, such as strikes, unsuccessful union negotiations, and other workforce disruptions.
• Economic downturns and recessions could negatively impact business by reducing consumer and customer spending.

Future Outlook

The company expects the May 2024 Restructuring Plan to improve income from operations by approximately $25.0 million per year in fiscal 2026 and beyond. Additional costs related to the Restructuring Plan are not expected to be significant during fiscal 2026. The company is currently assessing the impact of the recently enacted U.S. One Big Beautiful Bill Act (OBBBA) on its consolidated financial statements, with certain provisions applicable to years beginning after fiscal 2026. The claims administration process for the Illinois EO litigation settlement is expected to continue through the fourth quarter of fiscal 2026.

Management Comments

• "WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe."
• Restructuring actions were "designed to enhance profitability and improve efficiency."
• Restructuring actions are "expected to improve income from operations by approximately $25.0 million per year in fiscal 2026 and beyond."

Industry Context

The company's growth is largely driven by global demographic trends, specifically the aging population entering prime healthcare consumption years. This trend, coupled with advancements in healthcare delivery, acceptance of new technologies, and a desire for operational efficiency among customers, is increasing demand for medical procedures like endoscopies and colonoscopies, thereby boosting demand for STERIS's infection prevention products and services. The company's focus on healthcare, medical device, and pharmaceutical customers aligns with these long-term industry tailwinds.

Comparison to Industry Standards

• NA

Legal Proceedings

• The company entered into binding confidential term sheets and settlement agreements to pay up to $48.2 million to resolve substantially all pending personal injury claims related to ethylene oxide (EO) emissions from a Lake County, Illinois facility (2005-2008). The company denies liability.
• Received two Notices of Deficiency from the IRS regarding deemed dividend inclusions and associated withholding tax for fiscal/calendar year 2018, asserting a cumulative tax liability of approximately $50.0 million. The company is contesting these assertions and has filed petitions with the U.S. Tax Court, without establishing reserves.

Stakeholder Impact

• Shareholders: Benefited from increased net income, diluted EPS, and higher cash dividends per share. The ongoing share repurchase program also offers potential for future value.
• Employees: Approximately 300 positions were eliminated as part of the restructuring plan, impacting a portion of the workforce.
• Customers: Continued expansion of product and service offerings through tuck-in acquisitions aims to provide enhanced solutions in infection prevention and healthcare.
• Creditors: The company's debt-to-total capital ratio improved, and interest expense decreased due to lower principal debt, indicating a stronger financial position for creditors.
• Community (Lake County, Illinois): The settlement of EO litigation addresses past environmental concerns and provides compensation to affected plaintiffs, potentially improving community relations.

Next Steps

• Continue assessing the impact of the U.S. One Big Beautiful Bill Act (OBBBA) on consolidated financial statements.
• Proceed with the claims administration process for the Illinois EO litigation settlement, expected to continue through Q4 fiscal 2026.
• Focus on ongoing research and development initiatives to enhance sterile processing technologies, procedural products, and gastrointestinal endoscopy devices.
• Utilize the remaining $300.0 million under the Board-authorized share repurchase program as deemed appropriate.

Key Dates

Recommendation

The filing demonstrates exceptional financial performance with strong revenue growth across all segments, significant improvements in gross profit and operating income, and robust free cash flow generation. The company has successfully reduced its debt burden and improved its capital structure, while also effectively managing restructuring costs. The increased dividend and remaining share repurchase authorization signal confidence in future performance. Despite some increases in SG&A and tax rate, the overall trajectory is highly positive, suggesting strong potential for continued shareholder value creation.

Keywords

STERIS, Healthcare, Applied Sterilization Technologies, Life Sciences, Infection Prevention, Medical Devices, Pharmaceuticals, Q1 2026 Earnings, SEC 10-Q, Financial Results, Revenue Growth, Profitability, Cash Flow, Debt Reduction, Restructuring, Ethylene Oxide Litigation, Tax Reform